Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BPC‑157 is a synthetic pentadecapeptide (15 amino acids) originally derived from a protein found in human gastric juice. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Preclinical studies suggest that BPC‑157 has cytoprotective, anti-inflammatory, and tissue-regenerative properties, promoting healing of skin, muscle, bone, ligaments, tendons, and various organs. Proposed mechanisms include upregulation of growth factors involved in tissue repair and regeneration (such as VEGFR2), modulation of nitric oxide pathways for vascular function and blood flow, antioxidant activity via scavenging reactive oxygen species due to its structure with multiple carboxylic groups, and possible effects on gene expression related to angiogenesis and inflammation. Despite these findings in animal models or cell culture studies—and some use in functional medicine—BPC‑157 is not approved for any medical indication by regulatory agencies. It remains an experimental compound with no published clinical trial data supporting safety or efficacy in humans[1][2][3][5][6][7][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bpc-157.